ID: 4108 | Pages: 148 | October 2017 | Region: Asia Pacific
The Asia-pacific Migraine Drug Market was worth USD 0.66 billion in 2016 and estimated to be growing at a CAGR of 5.51 %, to reach USD 0.86 billion by 2021.The chronic daily headache (CDH) prevalence in Asia might be lower when compared to global average. However, Data collected based on population for Chronic Migraine (CM) remains low and there are many variations in classification.
Asia-Pacific Migraine Drug Market is increasing at a slow rate due to growth in generalization of drugs. Market is witnessing huge number of unmet needs because of no permanent cure for disease. This attracted investors to make huge investments in R&D. Companies which manufacture and sell drugs which show efficacy profile and high safety are estimated to be competitive to their peers.
The growing requirement for new treatment choices has driven to the improvement of new devices, for example, antimigraine devices and headbands in the market. For example, Cefaly Transcutaneous Electrical Nerve Stimulation devices is a FDA affirmed devices for headache treatment. This device animates the trigeminal nerve by emanating electric streams and gives reduction from headache. Expanding spending in new research exercises and novel item advancements are relied upon to quicken the development and improvement of this market throughout the following four years.
Market can be segmented by Treatment and Therapeutic class. Treatment can be further segmented into Preventive and Absorptive. Therapeutic class can be further segmented into triptants, ergots and others.
Key players in the market are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories.The other prominent vendors the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm,Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories, OptiNose, Pfizer, Pozen, Eisai, Raptor, RedHill, SUDA, Teva, , Aegis Therapeutics, Merck, TG Therapeutics, NValeant, Winston Pharmaceuticals, Allergan, and Zogenix.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Introduction
5.1.2 Preventive
5.1.3 Abortive
5.1.4 Y-o-Y Growth Analysis, By Treatment
5.1.5 Market Attractiveness Analysis, By Treatment
5.1.6 Market Share Analysis, By Treatment
5.2 Therapeutic
5.2.1 Introduction
5.2.2 Triptents
5.2.3 Ergots
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By Therapeutic
5.2.6 Market Attractiveness Analysis, By Therapeutic
5.2.7 Market Share Analysis, By Therapeutic
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment
6.1.3.3 By Therapeutic
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment
6.1.4.3 By Therapeutic
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment
6.1.5.3 By Therapeutic
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Allergan
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Endo International
8.3 GlaxoSmithKline
8.4 Impax
8.5 Pfizer
8.6 Aegis Therapeutics
8.7 Alder Biopharmaceuticals
8.8 Astellas
8.9 AstraZeneca
8.10 Aeriel BioPharma
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Title | Price | Add To Cart |
© 2018 Market Data Forecast
All Rights Reserved.